Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 6.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,729,948 shares of the biotechnology company's stock after purchasing an additional 112,113 shares during the quarter. Vanguard Group Inc. owned about 1.21% of Aurinia Pharmaceuticals worth $15,535,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. SBI Securities Co. Ltd. purchased a new position in Aurinia Pharmaceuticals in the 4th quarter worth approximately $25,000. Blue Trust Inc. boosted its holdings in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after acquiring an additional 6,174 shares during the period. Virtu Financial LLC purchased a new position in Aurinia Pharmaceuticals in the 4th quarter worth approximately $96,000. Cibc World Markets Corp purchased a new position in Aurinia Pharmaceuticals in the 4th quarter worth approximately $113,000. Finally, FMR LLC boosted its holdings in Aurinia Pharmaceuticals by 44.8% in the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock worth $93,000 after acquiring an additional 3,919 shares during the period. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Up 5.1 %

Shares of AUPH traded up $0.40 during trading on Wednesday, reaching $8.29. The company's stock had a trading volume of 281,414 shares, compared to its average volume of 1,344,286. The company has a fifty day moving average of $7.98 and a two-hundred day moving average of $8.12. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.77 and a twelve month high of $10.67. The company has a market cap of $1.14 billion, a price-to-earnings ratio of -55.26 and a beta of 1.20. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CFO Joseph M. Miller sold 61,859 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the transaction, the chief financial officer now directly owns 633,515 shares of the company's stock, valued at $5,068,120. This represents a 8.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares in the company, valued at approximately $15,631,136. This represents a 9.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 343,898 shares of company stock valued at $2,753,094 in the last three months. Corporate insiders own 4.30% of the company's stock.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.